Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online February 1, 2023.
Article Versions
- Latest version (October 15, 2022 - 04:05).
- Latest version (November 1, 2022 - 09:40).
- Latest version (November 2, 2022 - 10:25).
- You are currently viewing a Latest version of this article (February 1, 2023 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2023 The Journal of Rheumatology
Author Information
- Laura C. Coates,
- Irene E. van der Horst-Bruinsma,
- Ennio Lubrano,
- Steph Beaver,
- Emma Drane,
- Baran Ufuktepe and
- Alexis R. Ogdie
- L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, Oxfordshire, UK.
- I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, ZH0D53, Amsterdam UMC/VU University Medical Centre, Amsterdam, the Netherlands.
- E. Lubrano, MD, MSc, PhD, Dipartimento di Medicina e Scienze, Della Salute "Vincenzo Tiberio," Università degli Studi del Molise, Campobasso, Italy.
- S. Beaver, MSc, Costello Medical Consulting Ltd, Cambridge, Cambridgeshire, UK.
- E. Drane, PhD, Costello Medical Consulting Ltd, Cambridge, Cambridgeshire, UK.
- B. Ufuktepe, MD, PhD, UCB Pharma A.S. (Turkey), Istanbul, Turkey.
- A.R. Ogdie, MD, MSCE, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
-
This study was sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Costello Medical, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
LCC received grant/research support from AbbVie, Amgen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB Pharma; received consulting fees from AbbVie, Amgen, Biogen, BI, Celgene, Domain, Gilead, Janssen, and Lilly; and is on the speaker's bureau for AbbVie, Amgen, Biogen, Celgene, Gilead, GSK, Janssen, Lilly, medac, Novartis, Pfizer, and UCB Pharma. IEvdHB received grant/research support from AbbVie, MSD, and Pfizer; is a consultant for AbbVie, MSD, Novartis, and UCB Pharma; and is on the speaker's bureau for AbbVie, BMS, MSD, and Pfizer. EL is a consultant for AbbVie, Celgene, Novartis, Pfizer, and UCB Pharma. SB and ED are employees of Costello Medical. BU is an employee of UCB Pharma. ARO received grant/research support for the researcher's institution from Pfizer and Novartis to the University of Pennsylvania and from Amgen to Forward/NDB and is a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Eli Lilly, Janssen, Novartis, and Pfizer.
Address correspondence to Dr. L.C. Coates, University of Oxford, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford, OX3 7HE, UK . Email: laura.coates@ndorms.ox.ac.uk.
Accepted for publication September 28, 2022.
